Summary
Background The immunopathogenesis of severe COVID-19 is incompletely understood. Remdesivir is not recommended in mechanically ventilated (MV) patients. In the upper respiratory tract (URT) replicating (culturable) SARS-CoV-2 is recoverable for ∼ 4 to 8 days after symptom onset, however, there is paucity of data about the frequency or duration of replicating virus in the lower respiratory tract (i.e. the human lung).
Methods We undertook lung tissue sampling (needle biopsy), shortly after death, in 42 mechanically ventilated (MV) decedents during the Beta and Delta waves. An independent group of 18 ambulatory patents served as a comparative control. Lung biopsy cores from decedents underwent viral culture, histopathological analysis, electron microscopy, transcriptomic profiling, immunohistochemistry and cell-based flow cytometry of deconstructed tissue.
Findings 38% (16/42) of MV decedents had culturable virus in the lung for a median of 15 days (persisting for up to 4 weeks) after symptom onset compared to < ∼5 days in the URT of ambulatory patients. Lung viral culture positivity was not associated with comorbidities or steroid use. Delta but not Beta variant lung culture positivity was associated with accelerated death and secondary bacterial infection (p<0.05). NP culture was negative in 23.1% (6/26) of decedents despite lung culture positivity. This, hitherto, undescribed bio-phenotype of lung-specific persisting viral replication was associated with an enhanced transcriptomic pulmonary pro-inflammatory response but concurrent with viral culture positivity.
Interpretation In a sizable subset of patients with acute COVID-19, concurrent, rather than sequential active viral replication continues to drive a heightened pro-inflammatory response in the human lung beyond the second week of illness (despite lack of viral replication in the URT) and was associated with variant-specific increased mortality and morbidity. These findings have potential implications for the design of interventional strategies and clinical management of patients with severe COVID-19 disease.
Funding South African Medical Research Council.
Evidence before this study Previous investigations to understand SARS-CoV-2 viral shedding (determined by PCR or antigen testing) have extensively focused on samples from the upper respiratory tract. The widely accepted view is that acute severe SARS-CoV-2 infection is characterised by a viral replicative phase in the first week of symptomatic illness followed by a pro-inflammatory immunopathologic phase peaking in the second and third weeks of illness. However, it remains unclear whether detection of SARS-CoV-2 beyond 2 weeks after symptom onset in published studies represent active replication competent virus because it may represent residual genomic or antigenic material in the tissue. Indeed, active replicating virus using serial culture has been shown to only persist for up to approximately one week after symptom onset in the upper respiratory tract. We could not find any published studies that comprehensively interrogated the upper and lower respiratory tract for culturable virus and mapped out their related clinical determinants and host immunological status. We hypothesised that there is compartment-specific uncoupling of viral replication in acute severe COVID-19 i.e. replicating virus, can persist in the lower respiratory tract beyond 10 days from symptoms onset, independent of its persistence in the upper respiratory tract, and this persistence may be associated with altered pulmonary immunity, and would have implications for antiviral and immunomodulatory therapy.
Added value of this study We have identified a, hitherto, undescribed bio-phenotype of acute severe COVID-19 characterised by persisting viral replication in the lung for up to 4 weeks after symptom onset. This phenotype was associated with variant-specific accelerated death and a higher rate of secondary bacterial infection. We further found that this phenotype of replicating viral persistence was also associated with an exaggerated inflammatory response and attenuated T-cell immunity in the lung (based on histopathological and transcriptomic studies). This challenges the traditional view that viral replication occurs during the first 5 to 10 days of illness, which is followed by an effector or hyperinflammatory phase. This is the first study, to our knowledge, to systematically culture virus from the human lung and map out its related clinical determinants, and which describes the human lung transcriptomic profile of culture-positive versus culture-negative patients with severe COVID-19 disease.
Implications of all the available evidence The Infectious Disease Society of America (and many other global guidelines) currently recommend the use of antivirals like remdesivir for only 5 days in hospitalised patients, and do not recommend the use of antiviral agents in mechanically ventilated patients (conditional recommendation). However, our data have implications for patient management, and suggest that a subset of patients may likely benefit from antiviral therapy and possibly extended immunomodulatory therapy. Further clinical studies are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the South African Medical Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Human Research Ethics Committee (HREC) of the University of Cape Town (HREC approval number 866/2020) and University of Witwatersrand (HREC approval number M200313). Biosafety approvals were obtained from the Faculty Biosafety Committee of the University of Cape Town (IBC008-2021).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript was initially submitted as a brief report, but has subsequently been revised as a full length article.
Data Availability
Individual participant data will be made available to researchers who provide a protocol that is approved by their respective human research ethics committee. All protocols will be reviewed and approved by the MITS consortium trial steering committee up to five years following publication. A data sharing agreement (DTA) will need to be concluded between the representatives of the requesting institution and the University of Cape Town Lung Institute. Data sharing requests should be directed to keertan.dheda{at}uct.ac.za
